Co-Diagnostics receives Australian patent covering Co-Dx PCR platform technologies for nucleic acid detection and analysis: Salt Lake City Wednesday, December 31, 2025, 11:00 Hrs ...

As the federal health emergency ended May 11 and COVID numbers are on the rise, here’s how you can still access tests, at-home and PCR. (Michael Bocchieri/Getty Images) It’s that time again: COVID-19 ...

Last week, I was about to go on a date, and because I'm severely immunocompromised, we agreed he would take a COVID test using one of my rapid home molecular tests. It was a courtesy—he felt perfectly ...

New COVID-19 restrictions for international travel and other activities are fueling consumer demand for highly accurate polymerase chain reaction, or PCR, tests with rapid turnaround times. Some ...

If you had COVID-19 symptoms in 2020, you probably would have masked up and braved a visit to a laboratory, doctor’s office, or clinic to get a polymerase chain reaction (PCR) test. A health care ...

This decision, well within current norms for care, was nonetheless consequential: The president was forced to cancel a trip to advocate for legislation in support of the domestic semiconductor ...

Co-Diagnostics, Inc. (Nasdaq: CODX) ("Co-Dx" or "the Company"), a molecular diagnostics company with a unique, patented ...

A PCR test is often considered the gold standard for detecting coronavirus infection. It’s the test some employers want employees to take before returning to work after having Covid-19, and the one ...

The Australian patent represents the first patent granted for the Company's new point-of-care testing platform ...